It's been 8 months in November since we were told:
"the U.S. FDA supports an accelerated approval pathway for rexlemestrocel-L, Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product, in patients with end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD)"
..... and still no meeting (that we know of) ? Get on with it ... lol
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.49 |
Change
0.000(0.00%) |
Mkt cap ! $3.187B | |||
| Open | High | Low | Value | Volume |
| $2.53 | $2.55 | $2.48 | $9.615M | 3.829M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $2.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.50 | 4078 | 2 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |